home / stock / oyst / oyst news


OYST News and Press, Oyster Point Pharma Inc. From 08/08/22

Stock Information

Company Name: Oyster Point Pharma Inc.
Stock Symbol: OYST
Market: NASDAQ
Website: oysterpointrx.com

Menu

OYST OYST Quote OYST Short OYST News OYST Articles OYST Message Board
Get OYST Alerts

News, Short Squeeze, Breakout and More Instantly...

OYST - Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022

Conference Call and Webcast Scheduled for August 11, 2022, 4:30 p.m. ET PRINCETON, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-clas...

OYST - Oyster Point Pharma Announces Expanded Patient Access to TYRVAYA®

TYRVAYA Now Covered by Commercial Prescription Drug Plans Managed by the Nation’s Top Three Pharmacy Benefit Manager (PBM) Group Purchasing Organizations (GPOs) Expanding Patient Access Programs to Include More Eligible Patients with Dry Eye Disease Launch t...

OYST - Oyster Point stock rises 11% after H.C. Wainwright begins coverage with Buy rating

Oyster Point Pharma ( NASDAQ: OYST ) is trading ~11% higher after H.C. Wainwright initiated coverage with a Buy rating and a price target of $20. H.C. Wainwright analyst Matthew Caufield said the company has a "differentiated" dry eye nasal spray approval compleme...

OYST - Oyster Therapeutics: State Of Business Is Confounding

OYST has an approved product that is highly competitive against a blockbuster drug. They seem to have executed commercialization pretty well, except in the bottom line. Here, they have abysmally failed to make any money. Oyster Point Pharma, Inc. (OYST) has an approved p...

OYST - Oyster Point Pharma implementing cost-cutting plan with up to 50 jobs axed

Oyster Point Pharma (NASDAQ:OYST) will implement a cost-savings plan that it says will lead to $6M-$8M in savings this year but also includes laying off up to 50 workers. The ophthalmic diseases focused biotech said it expects savings of $40M-$48M in 2023. Oyster Point said that the move will...

OYST - Oyster Point Pharma Announces Operating Expense Streamlining Plan

Plan to Continue to Drive TYRVAYA ® Launch with Approximately 150-200 Field-Based Sales Resources Plan Expected to Deliver Expense Savings of Approximately $6-8 Million in the Second Half of 2022 and $40-48 Million in 2023 Company to Refocus Research and D...

OYST - Oyster Point Pharma Research Selected for Top 5 Poster Session at American Optometric Association's Optometry's Meeting®

PRINCETON, N.J., June 15, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced tha...

OYST - Oyster Point Pharma, Inc.'s (OYST) CEO Dr. Jeffrey Nau on Q1 2022 Results - Earnings Call Transcript

Oyster Point Pharma, Inc. (OYST) Q1 2022 Earnings Conference Call May 5, 2022, 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and CEO Dan Lochner - Chief Financial Officer John Snisarenko - Chief Commercial Officer Conference Call P...

OYST - Oyster Point Pharma, Inc. (OYST) Q1 2022 Earnings Call Transcript

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q1 2022 Earnings Call May 05, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q1 2022 Earnings Call Transcript...

OYST - Oyster Point Pharma Reports First Quarter 2022 Financial Results and Recent Business Highlights

TYRVAYA ® Nasal Spray Net Product Revenue of $2.7 Million in Q1’22 Approximately 19,000 TYRVAYA Prescriptions Filled During the Quarter, with Prescriptions Written by Over 4,500 Unique Eye Care Professionals Expansion of Commercial Coverage fo...

Previous 10 Next 10